c-kit (d816h)

Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally administered multi-targeted tyrosine kinase inhibitor effective against mutant forms of c-Kit, PDGFRα, Flt3, c-Met, and c-Ret, and it suppresses DNA repair by inhibiting the RAD51 protein, contributing to its antineoplastic activity[1][2][3][4].

c-Kit-IN-12 (Compound 2a) is a potent c-Kit inhibitor with an IC50 of less than 10 nM across four KIT mutant cell models [BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, EX11 DEL/V654A]. It is useful for research into c-Kit-associated diseases or disorders, such as cancer.

(S)-c-Kit-IN-12 (Compound 2b) is a potent c-Kit inhibitor with an IC50 of less than 10 nM against four KIT mutant cell models [BAF3 KIT EX11 DEL, EX11 DEL/D816H, EX11 DEL/T670I, EX11 DEL/V654A]. This compound is useful for researching diseases or disorders related to c-Kit, such as cancer.